(1) According to SEER Database for US the incidence is 1.9 per 100000. https://seer.cancer.gov/statfacts/html/cmyl.html;
(2) Huang X, et al. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012 Jun 15;118(12):3123-7.;
(3) NCCN guidelines
(4) National Comprehensive Cancer Network. (2019). Chronic Myeloid Leukemia (version 1.2019). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf;
(5) O'Brien S, et al. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw. 2014 Nov;12(11):1590-610.;
(6) Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time"quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia. 2003 Dec;17(12):2474-86.
(7)Zackon, I., Beeks, A., Wei, D., Wentworth, C., Guo, J., McDermott, C., Jadhav, K., Herms, L., Damon, A., Sadek, I., & Benton, C. B. (2024). Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting. Blood, 144(Supplement 1), 6611.
https://doi.org/10.1182/blood-2024-210681